2013 BRFSS Asthma Call-Back Survey Prevalence Tables

TABLE 9. Estimated percent using an inhaled corticosteroid in the past 3 months among adults1 with current2 or active3 asthma status by state/territory – BRFSS Asthma Call-back Survey Land Line Sample, United States, 2013

State/Territory Current Active
Sample
size±
% SE§ 95% CI Sample
size
% SE 95% CI
Alabama 129 36.7 7.8 (21.4 – 52.0) 138 31.7 7.2 (17.6 – 45.8)
Arizona 103 38.3 10.5 (17.7 – 58.9) 105 39.4 10.5 (18.8 – 60.0)
California 168 28.5 4.9 (18.9 – 38.1) 184 31.4 4.7 (22.2 – 40.6)
Connecticut 212 48.8 6.7 (35.7 – 61.9) 232 46.7 6.4 (34.2 – 59.2)
Florida 724 33.4 4.9 (23.8 – 43.0) 767 34.4 4.8 (25.0 – 43.8)
Georgia 122 32.4 7.1 (18.5 – 46.3) 132 31.5 6.8 (18.2 – 44.8)
Hawaii 110 42.1 10.3 (21.9 – 62.3) 110 40.2 10.4 (19.8 – 60.6)
Indiana 319 44.5 5.4 (33.9 – 55.1) 334 43.4 5.2 (33.2 – 53.6)
Iowa 208 39.0 7.6 (24.1 – 53.9) 212 38.6 7.2 (24.5 – 52.7)
Kansas 627 32.1 3.3 (25.6 – 38.6) 655 32.6 3.3 (26.1 – 39.1)
Kentucky 334 31.1 4.6 (22.1 – 40.1) 363 28.1 4.2 (19.9 – 36.3)
Louisiana 125 28.4 6.3 (16.1 – 40.7) 144 19.2 5.1 (9.2 – 29.2)
Maine 223 30.4 4.6 (21.4 – 39.4) 240 29.2 4.4 (20.6 – 37.8)
Maryland 225 34.0 5.5 (23.2 – 44.8) 243 32.8 5.3 (22.4 – 43.2)
Massachusetts 142 34.5 8.2 (18.4 – 50.6) 151 32.0 7.3 (17.7 – 46.3)
Michigan 461 41.1 4.1 (33.1 – 49.1) 494 38.9 3.9 (31.3 – 46.5)
Mississippi 214 28.6 5.6 (17.6 – 39.6) 217 29.3 5.8 (17.9 – 40.7)
Missouri 213 31.7 5.0 (21.9 – 41.5) 220 31.9 4.9 (22.3 – 41.5)
Montana 257 24.8 4.8 (15.4 – 34.2) 275 23.9 4.5 (15.1 – 32.7)
Nebraska 262 27.2 5.3 (16.8 – 37.6) 283 25.1 4.6 (16.1 – 34.1)
Nevada 100 28.7 7.5 (14.0 – 43.4) 115 27.5 7.1 (13.6 – 41.4)
New Hampshire 216 21.7 3.7 (14.4 – 29.0) 228 20.1 3.5 (13.2 – 27.0)
New Jersey 251 29.5 5.4 (18.9 – 40.1) 282 24.7 4.7 (15.5 – 33.9)
New Mexico 223 34.5 5.2 (24.3 – 44.7) 238 33.3 5.1 (23.3 – 43.3)
New York 112 N/A N/A (N/A – N/A) 112 24.1 7.2 (10.0 – 38.2)
North Carolina 106 43.4 8.7 (26.3 – 60.5) 124 41.3 8.0 (25.6 – 57.0)
Ohio 244 40.6 6.1 (28.6 – 52.6) 256 41.1 6.0 (29.3 – 52.9)
Oklahoma 222 25.9 4.0 (18.1 – 33.7) 231 26.5 3.9 (18.9 – 34.1)
Oregon 161 39.3 7.7 (24.2 – 54.4) 178 37.6 7.4 (23.1 – 52.1)
Pennsylvania 247 42.6 5.9 (31.0 – 54.2) 265 38.1 5.4 (27.5 – 48.7)
Rhode Island 196 33.1 5.4 (22.5 – 43.7) 208 32.9 5.3 (22.5 – 43.3)
Texas 208 31.7 7.4 (17.2 – 46.2) 231 30.9 7.1 (17.0 – 44.8)
Utah 303 32.7 6.1 (20.7 – 44.7) 320 32.2 5.8 (20.8 – 43.6)
Vermont 189 33.6 5.7 (22.4 – 44.8) 201 34.1 5.6 (23.1 – 45.1)
Washington 286 26.3 3.9 (18.7 – 33.9) 294 28.1 4.1 (20.1 – 36.1)
West Virginia 125 29.2 4.7 (20.0 – 38.4) 125 29.4 4.7 (20.2 – 38.6)
Wisconsin 188 39.5 6.7 (26.4 – 52.6) 190 35.8 7.3 (21.5 – 50.1)
Puerto Rico 205 35.5 5.8 (24.1 – 46.9) 246 31.9 5.2 (21.7 – 42.1)
38 state total 8,760 33.1 1.4 (30.4 – 35.8) 9,343 32.8 1.3 (30.3 – 35.3)
Median   33.1       32.0    
Range   21.7-48.8       19.2-46.7    

1 Aged ≥ 18 years

2 “Yes” response to “Do you still have asthma?”

3 Reported any of the following during the past year: asthma medication use, asthma symptoms, or MD visits for asthma

± Landline sample size excludes “DK/Refused”

§ Standard error

Confidence interval

N/A: Estimate not available (N/A) if the unweighted sample size for the denominator was < 50 or if the relative standard error was > 0.30